Intervention by Clinical pharmacists in Cardiovascular Disease Management: Evidence from Intervention Studies
Downloads
Cardiovascular diseases (CVDs) represent a range of chronic disorders impacting blood vessels and heart, contributing to the reduction of the quality of life and contributing significantly to increased rate of mortality as well as morbidity. Clinical pharmacists contribute as integral members of the healthcare team concerning treatment of chronic diseases, involving cardiovascular conditions. This review aims to present the responsibility of clinical pharmacists in the treatment of patients diagnosed with cardiovascular diseases. This review was performed as a structured narrative review. Several studies published in Google Scholar, PubMed, and Science Direct which issued between 2012 and 2024 were reviewed. The review summarizes evidence on clinical outcomes, including blood pressure and glycemic control, lipid profile outcomes, medication adherence, and economic impact. By integrating findings across diverse healthcare settings, existing evidence suggests that the active participation of clinical pharmacists may be associated with an improvements in patients counseling, risk factors control, medication safety, medication adherence, and a reduction in hospitalization and medication costs.
1. Netala VR, Teertam SK, Li H, Zhang Z. A comprehensive review of cardiovascular disease management: cardiac biomarkers, imaging modalities, pharmacotherapy, surgical interventions, and herbal remedies. Cells. 2024;13(17):1471. https://doi.org/10.3390/cells13171471.
2. Motlohi NF, Mensah KB, Padayachee N, Petrus R, Alqifari SF, Bangalee V. A multicenter cross-sectional survey of the role of community pharmacists, attitudes, and perceptions in preventing and controlling cardiovascular diseases. PLoS One. 2025;20(2):e0314487. https://doi.org/10.1371/journal.pone.0314487.
3. Wang MS, Deng JW, Geng WY, Zheng R, Xu HL, Dong Y, Huang WD, Li YL. Temporal trend and attributable risk factors of cardiovascular disease burden for adults 55 years and older in 204 countries/territories from 1990 to 2021: an analysis for the Global Burden of Disease Study 2021. Eur J Prev Cardiol. 2025;32(7):539-52. https://doi.org/10.1093/eurjpc/zwae384.
4. Hossain MS, Dulal DD, Faysal DF. Prevalence of cardiovascular disease and associated risk factors among adults. Dinkum J Med Innov. 2024;3(05):379-90.
5. Alhuneafat L, Ta'ani OA, Jabri A, Tarawneh T, ElHamdan A, Naser A, Al-Bitar F, Alrifai N, Ghanem F, Alaswad K, Alqarqaz M, Van't Hof JR, Adabag S, Virani SS. Cardiovascular disease burden in the Middle East and North Africa region. Curr Probl Cardiol. 2024;49(3):102341. https://doi.org/10.1016/j.cpcardiol.2023.102341.
6. Perone F, Spadafora L, Pratesi A, Nicolaio G, Pala B, Franco G, Ruzzolini M, Ambrosetti M. Obesity and cardiovascular disease: risk assessment, physical activity, and management of complications. Int J Cardiol Cardiovasc Risk Prev. 2024;23:200331. https://doi.org/10.1016/j.ijcrp.2024.200331.
7. Mambo A, Yang Y, Mahulu E, Zihua Z. Investigating the interplay of smoking, cardiovascular risk factors, and overall cardiovascular disease risk: NHANES analysis 2011–2018. BMC Cardiovasc Disord. 2024;24(1):193. https://doi.org/10.1186/s12872-024-03838-7.
8. Rattanavipanon W, Chaiyasothi T, Puchsaka P, Mungkornkaew R, Nathisuwan S, Veettil SK, Chaiyakunapruk N. Effects of pharmacist interventions on cardiovascular risk factors and outcomes: an umbrella review of meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2022;88(7):3064-77. https://doi.org/10.1111/bcp.15279.
9. Biradar SM, Kohima B, Nayak V, Nandikol S, Biradar SM, Warad V, Byakod SM, Hunasagi BS. Assessment of drug related problems and pharmacist interventions in inpatients with cardiovascular disease. 2022;18(5):536-43. https://doi.org/10.20996/1819-6446-2022-10-07.
10. Lavanya S, Patel N, Purani A, Patel K. Impact of clinical pharmacist intervention on medication adherence in patients with cardiovascular disease. Thai J Pharm Sci. 2022;46(4):462-6. https://doi.org/10.56808/3027-7922.2629.
11. Kreft SB, Wehner C, Renier CM, Haller IV, Milbrandt S. Effects of pharmacist-led education on medication knowledge and confidence in cardiac rehabilitation patients. J Cardiopulm Rehabil Prev. 2023;43(3):226-9. https://doi.org/10.1097/HCR.0000000000000784.
12. Shi FH, Yu BB, Shen L, Xu L, Jiang YH, Gu ZC, Lin HW, Li H. The importance of clinical pharmacists in improving blood glucose and lipid levels in patients with diabetes and myocardial infarction. Diabetes Metab Syndr Obes. 2023;16:2733-2744. https://doi.org/10.2147/DMSO.S425960.
13. Delage C, Lelong H, Brion F, Blacher J. Effect of a pharmacist-led educational intervention on clinical outcomes: a randomised controlled study in patients with hypertension, type 2 diabetes and hypercholesterolaemia. Eur J Hosp Pharm. 2021;28(e1):e197-202.
14. Sahu DK, Chandu HN. The impact of clinical pharmacists on cardiovascular disease management in Spain: a community pharmacy-based intervention study. J Angiother. 2024;8(9):1-7. https://doi.org/10.25163/angiotherapy.899886.
15. Alotaibi MS, Altebainawi AF, Alharbi AS, Alfaraj LA, Alenazi MA, Alkhrshawy FF. Implementation and outcome of clinical pharmacist-led anticoagulation clinic at cardiac center: a retrospective cohort study. Saudi J Clin Pharm. 2024;3(3):154-61.
16. Desai NR, Farbaniec M, Karalis DG. Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease. Clin Cardiol. 2023;46(1):13-21. https://doi.org/10.1002/clc.23935.
17. Jackson IL, Ukwe CV. Clinical outcomes of pharmaceutical care intervention in HIV positive patients with hypertension: a randomized controlled study. J Clin Pharm Ther. 2021;46(4):1083-1094. https://doi.org/10.1111/jcpt.13400.
18. Huynh BH, Nathisuwan S, Tragulpiankit P, Nguyen VD, Huynh NH, Vu TLA, Huynh LTH, Vo HT. Drug-related problems and pharmacists’ interventions in hypertensive outpatients: a multicenter prospective study in 3 Vietnamese hospitals. J Pharm Technol. 2023. https://doi.org/10.1177/87551225231199358.
19. Ghanbarlou N, Rekha MM, Nazi M. A prospective observational and interventional study on the role of doctor of pharmacy/clinical pharmacist in identification, reporting and minimization of drug-related problems in pulmonary and cardiology departments of ESI hospital. Int J Pharm Pharm Sci. 2021;13(3):51-4. https://doi.org/10.22159/ijpps.2021v13i3.38152.
20. Barragan NC, Chen SW, Abraham JE, Chu M, Kuo T. Narrowing cardiovascular disease health disparities by advancing the role of pharmacists through a multisector consortium. J Public Health Manag Pract. 2024;30(Suppl):S130-6. https://doi.org/10.1097/PHH.0000000000001929.
21. Valenzuela A, Abushoumi F, Al Dobayan Z, Al-Ghamdi F. Assessment of clinical pharmacist-initiated optimisation of pharmacotherapy in patients with acute coronary syndrome. Int J Pharm Qual Assur. 2024;15(3):2030-6. https://doi.org/10.25258/ijpqa.15.3.138.
22. Al-Taani GM, Muflih S, Al-Azzam S, Alzoubi KH. Costs saved and avoided from pharmacist interventions to address drug-related problems identified from outpatient clinics in Jordan. PLoS One. 2024;19(6):e0302287. https://doi.org/10.1371/journal.pone.0302287.
23. Kido K, Colvin BM, Broscious R, Bongiorni S, Sokos G, Kamal KM. Economic impact of ambulatory clinical pharmacists in an advanced heart failure clinic. Ann Pharmacother. 2022;56(11):1203-9. https://doi.org/10.1177/10600280221075755.
24. Farhana L, Rahayu FP, Sholihah S, Sweileh W, Abdulah R, Alfian SD. Effectiveness of pharmacist-led intervention on medication adherence in chronic diseases: a systematic review of randomized controlled trials. Patient Prefer Adherence. 2025;19:2161-78. https://doi.org/10.2147/PPA.S530503.
25. Elnaem MH, Rosley NFF, Alhifany AA, Elrggal ME, Cheema E. Impact of pharmacist-led interventions on medication adherence and clinical outcomes in patients with hypertension and hyperlipidemia: a scoping review of published literature. J Multidiscip Healthc. 2020;13:635-45.
26. Al-Arkee S, Al-Ani O. Community pharmacist-led interventions to improve medication adherence in patients with cardiovascular disease: a systematic review of randomised controlled trials. Int J Pharm Pract. 2023. https://doi.org/10.1093/ijpp/riad013.
27. Mohan AR, Majd Z, Johnson ML, Essien EJ, Barner JC, Serna O, Gallardo E, Fleming ML, Ordonez N, Holstad MM, Abughosh S. A motivational interviewing intervention to improve adherence to ACEIs/ARBs among nonadherent older adults with comorbid hypertension and diabetes. Drugs Aging. 2023;40:377-90. https://doi.org/10.1007/s40266-023-01008-6.
28. Östbring MJ, Eriksson T, Petersson G, Hellström L. Effects of a pharmaceutical care intervention on clinical outcomes and patient adherence in coronary heart disease: the MIMeRiC randomized controlled trial. BMC Cardiovasc Disord. 2021;21(1):367.
29. Martinez D, Gopalani RB, de Almeida K, Falli M, Davis L, Murray JM, Iluyomade A, Rambhatla T, Fialkow J. Pharmacist-led care in collaboration with a cardiovascular team to improve the management of atherosclerotic cardiovascular disease risk in hospitalized patients. Nurs Health Sci Res J. 2024;7(1):163-75. https://doi.org/10.55481/2578-3750.1198.
30. Santschi V, Chiolero A, Paradis G, Colosimo AL, Burnand B. Pharmacist interventions to improve cardiovascular disease risk factors in diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care. 2012;35(12):2706-17. https://doi.org/10.2337/dc12-0369.
31. Alshehri AA, Jalal Z, Cheema E, Haque MS, Jenkins D, Yahyouche A. Impact of the pharmacist-led intervention on the control of medical cardiovascular risk factors for the primary prevention of cardiovascular disease in general practice: a systematic review and meta-analysis of randomised controlled trials. Br J Clin Pharmacol. 2020;86(1):29-38. https://doi.org/10.1111/bcp.14164.
